재규어 헬스 (JAGX)

Jaguar Health Inc Stock (JAGX) dropped by 24.81% from $0.462 to $0.3474 in the trading on Tuesday November 21, 2023. The reason why JAGX stock down today is due to the update on Phase 3 trial for plant-based drug. Jaguar Health announced that its subsidiary, Napo Pharmaceuticals, is yet to receive topline results from its OnTarget Phase 3 trial for the plant-based drug Crofelemer. This pivotal study aims to assess Crofelemer's efficacy as a preventive treatment for cancer therapy-related diarrhea in adults. While topline results are expected soon, Jaguar Health (JAGX) refrained from providing a specific timeline.